预约演示
GT Medical Technologies Announces First Patient Enrolled in GESTALT Trial of GammaTile® Therapy for Newly Diagnosed Glioblastoma Brain Tumors
2022-10-11
合作放射疗法
This phase 4 clinical trial evaluates the use of GammaTile Therapy at the time of surgery combined with the standard Stupp protocol for patients with newly diagnosed glioblastomas.
TEMPE, Ariz., Oct. 11, 2022 /PRNewswire/ -- GT Medical Technologies, Inc. announced the enrollment of the first patient into the GESTALT (GammaTile Enhanced Stupp ALTernative Trial) of GammaTile Surgically Targeted Radiation Therapy (STaRT) for patients with newly diagnosed glioblastomas.
Continue Reading
The GESTALT Clinical Trial will include immediate radiation with GammaTile Therapy followed by the Stupp protocol.
Tweet this
Matthew E. Likens, President & CEO of GT Medical Technologies, Inc
Glioblastoma (GBM) is the most common GT Medical Technologies, Incr in adults, yet effective treatment remains a challenge. In 2005, the Stupp protocol became the standard of care—tumor resection, followed by adjuvant temozolomide (TMZ) and external beam radiation therapy (EBRT) several weeks post-surgery. Unfortunately, patient outcomes remain poor, and there have been few advancements over the last decades.
Glioblastoma (GBM)is the only GBM treaprimary malignant brain tumore past decade and one of only 7 FDA-cleared or -approved GBM treatments in the past 50 years. In clinical trials tumoratient case studies, GammaTile ThtemozolomideesTMZmediate radiation therapy at the time of surgical resection giving patients an effective treatment alternative for newly diagnosed malignant and recurrent brain tumors of all types.
GammaTiles are radiation implaGBM specifically designed for use in the brain. Each resorbable collagen GammaTile is embeddedGBMth Cs-131 radiation sources. The neurosurgeon implants GammaTiles in the cavity created by tumor removal. They begin working immediately to combat residual tumor cells.malignant and recurrent brain tumors
"Our goal is to demonstrate how starting radiation immediately at the completion of resection and combining it with the Stupp protocol can improve outcomes," said Matt Likens, president and CEO of GT Medical Technologies. "Since GBM is highly proliferative, approximately 50% of patients experience rapid early progression before they can start the Stupp protocol treatment."
"This is an important study built on sound clinical data with the potential to reshape how we approach glioblastoma treatments in the future. We are pleased to offer this study to our patients at MGT Medical Technologiesented Dr.GBMark Chen, the Lyle French Chair and Head of the Department of Neurosurgery, University of Minnesota Medical School. Dr. Chen played an instrumental role in designing the GESTALT Clinical Trial and leads the GESTALT Clinical Team at this site.
About GT Medical Technologies, Inc.glioblastomaUniversity of Minnesota Medical School
DrivenGT Medical Technologies, Inc.e and improve the lives of patients with brain tumors, a team of brain tumor specialists formed GT Medical Technologies and innovated GammaTile Therapy. FDA-cleared GammaTile Surgically Targeted Radiation Therapy (STaRT) is for all types of newly diagnosed malignant tumors and recurrent brain tumors. Embedded with radiation sources, the resorbable collagen GammaTiles are implanted at the completion of brain tumor removal surgery for immediate treatment—eliminating the standard delay for external beam radiation therapy. With this "one and done" treatment, patients receive radiation therapy as they go about their daily lives, without additional trips to the hospital or clinic. For more information, visit www.gtmedtech.com and follow @GammaTile on Twitter and LinkedIn.
Lori Kagan
[email protected]
SOURCE GT Medical Technologies
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-药物
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。